Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
06:35pm, Wednesday, 14'th Jan 2026
Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
01:00am, Monday, 12'th Jan 2026
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Confere
Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease
12:55am, Monday, 12'th Jan 2026
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat,
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
01:00am, Tuesday, 06'th Jan 2026
Allschwil, Switzerland – January 6, 2026 Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psori
Idorsia's daridorexant in women during menopausal transition age with insomnia
11:45am, Monday, 05'th Jan 2026
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
01:00am, Monday, 05'th Jan 2026
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hyperte
Idorsia (OTCMKTS:IDRSF) Shares Up 13% – What’s Next?
01:52am, Wednesday, 17'th Dec 2025
Idorsia Ltd (OTCMKTS:IDRSF - Get Free Report) shares shot up 13% during trading on Tuesday. The stock traded as high as $4.95 and last traded at $4.95. 1,350 shares traded hands during mid-day trading
Allschwil, Switzerland – December 9, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
11:45am, Monday, 10'th Nov 2025
Allschwil, Switzerland – November 10, 2025 Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension titled “Effe
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
11:45am, Wednesday, 05'th Nov 2025
Allschwil, Switzerland – November 05, 2025 Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia's endothelin receptor antagonist, will be
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
02:00am, Thursday, 30'th Oct 2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia's t
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
01:00am, Friday, 10'th Oct 2025
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB
Idorsia launches an offering of registered shares – to fund the company to overall profitability
11:45am, Thursday, 09'th Oct 2025
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB
Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China
01:00am, Monday, 22'nd Sep 2025
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVI
Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
01:00am, Friday, 19'th Sep 2025
Allschwil, Switzerland – September 19, 2025 Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hyperte
